Clinical Trial Update: Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis [Phase 1]

View source ↗

Summary

A Stanford-led Phase 1, single-center trial evaluated omalizumab (Xolair) in adults with atopic dermatitis; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Stanford University | Conditions: Atopic Dermatitis | Phase 1 | Status: COMPLETED